FSTX - PPD cut following Thermo Scientific deal Apellis and Iovance initiated as buys and more in today's analyst action

Multiple investment houses cut PPDFollowing yesterday's announcement that Thermo Fisher Scientific (TMO) would spend $17B to acquire PPD (PPD), several investment houses, including Truist, Deutsche Bank, and Baird, have cut PPD shares to sell.Truist analyst Sandy Draper cut PPD shares to hold due to the acquisition price of $47 being close to the firm's $47.50 price target.DB analyst George Hill cuts shares from buy to hold given that the purchase price is "relatively rich."Goldman Sachs sees 192% upside potential with ApellisGoldman Sachs analyst Madhu Kumar has initiated Apellis Pharmaceuticals (APLS) with a buy and a $130 price target, implying a 192% upside.He is confident in the risk/reward profile for the phase 3 DERBY/OAKS trial of intravitreal pegcetacoplan in geographic atrophy.Pegcetacoplan also is under investigation for paroxysmal nocturnal hemoglobinuria and has a PDUFA date of May 14, 2021 in that indication.Lifileucel, TIL therapy pipeline setting Iovance up for successLifileucel for melanoma, cervical cancer,

For further details see:

PPD cut following Thermo Scientific deal, Apellis and Iovance initiated as buys, and more in today's analyst action